Study Type
Interventional - Procedure
completed
The objective of the TIMACS study was to compare relative efficacy, safety, and cost effectiveness of a management strategy of coronary angiography and intervention performed within 24 hours of randomization versus delayed coronary angiography and intervention in patients after 36 hours with ACS.
Primary Endpoint
Adjudicated. Composite of death, myocardial (re-) infarction, or stroke. Secondary Points: Death/myocardial infarction (MI)/stroke/refractory ischemia/repeat intervention at discharge/30d/180d. Death/MI/stroke at discharge/30d/180d. Major bleeding at 30d. Each component of the primary outcome individually at discharge/30d/180d.
Study Design
Randomized, single blind (outcomes assessor), parallel group
NO. of Countries
14
NO. of Sites
38
NO. of Participants
3031
Study Period
2003-2008
Sponsor
PHRI
Sanofi
Canadian Institutes of Health Research (CIHR)
Shamir Mehta
Senior Scientist
Shamir Mehta
Senior Scientist
Shamir Mehta is a Senior Scientist with the Acute Coronary Syndrome and Interventional Cardiology research program at PHRI. He holds the Douglas A. Holder Endowed Chair and is a Professor of Medicine at McMaster University. Mehta directs the Royal College fellowship in interventional cardiology and leads the mitral and tricuspid valve transcatheter edge-to-edge repair programs at Hamilton Health Sciences and McMaster University. He completed his medical education and postgraduate training at the University of Toronto, followed by a research fellowship at McMaster University, supported by a Canadian Institutes of Health Research New Investigator Award.
At PHRI, he leads landmark clinical trials that evaluate revascularization strategies and new pharmacologic interventions for patients with acute coronary syndromes. Mehta is the Principal Investigator of the COMPLETE-2 trial, a 5,100-patient multinational study comparing physiology-guided and angiography-guided PCI strategies for treating non-culprit lesions in patients with acute coronary syndrome and multivessel coronary artery disease. This trial includes a large-scale intracoronary imaging study using optical coherence tomography to predict cardiovascular events. He also serves on the executive committee of the Librexia ACS trial, which is testing a novel Factor XIa inhibitor in acute coronary syndromes, and he is a steering committee member of OCEAN(a), focusing on targeted lowering of lipoprotein(a) with a novel small interfering RNA after acute coronary syndrome or PCI.
Dr. Mehta has published hundreds of research articles and has secured millions of dollars in peer-reviewed research grants from CIHR and industry. In 2022, he received the Canadian Cardiovascular Society’s Research Achievement Award. In 2024, he received the Canadian Association of Interventional Cardiology Outstanding Achievement Award.
